Concepedia

James K. Hogan

JK

11

Publications

667

Citations

11

H-Index

1992

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

James K. Hogan is an author at Vertex Pharmaceuticals (United States) specializing in medicine, biochemistry, and natural sciences.

Top concepts

MedicineBiochemistryNatural SciencesPharmacologyDrug DiscoveryMedicinal ChemistryBioanalysisMicrobiologyCell SignalingPharmacotherapy

Publications per year

1992–2015

11

Publications

11

Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.

David H.‐F. Teng, William L. Perry, James K. Hogan et al. · PubMed · 1997 · 193 citations

Signal Transduction Pathways, Human Mitogen-activated Protein, Cell Death +19

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

Immunology, Immunologic Mechanism, Janus Tyrosine Kinases +16

The Marine Cyanobacterial Metabolite Gallinamide A Is a Potent and Selective Inhibitor of Human Cathepsin L

Bailey W. Miller, Aaron J. Friedman, Hyukjae Choi et al. · Journal of Natural Products · 2013 · 76 citations · Full text

Engineering, Secondary Metabolite, Peptide Science +20

Investigation of protein refolding using a fractional factorial screen: A study of reagent effects and interactions

Melissa Swope Willis, James K. Hogan, Prakash Prabhakar et al. · Protein Science · 2005 · 74 citations · Full text

Fractional Factorial Screen, Protein Assembly, Molecular Biology +19

VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease

Sudipta Mahajan, James K. Hogan, Dina Shlyakhter et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 60 citations

Rows per page

1–5 of 11